Soliris

Biotech

Novartis touts new budding disease med as it battles AstraZeneca

Novartis is touting expanded data of its phase 3-stage rare disease med as it takes on a couple of AstraZeneca gems.
Max Bayer Dec 13, 2022 10:00am

Novartis takes another swipe at AstraZeneca's rare disease gems

Dec 8, 2022 10:28am

AstraZeneca's danicopan improves hemoglobin levels in phase 3

Sep 16, 2022 9:40am

CANbridge posts early-phase data on rival to AstraZeneca drug

Feb 7, 2022 8:35am

Novartis posts Soliris rival data, aims to be standard of care

Aug 31, 2020 8:15am

Genentech posts long-term data on near-approval Soliris rival

May 22, 2020 8:50am